Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00139373

Enrollment

Registered

2005-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2007-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supranuclear Palsy, Progressive

Keywords

Progressive supranuclear palsy, Frontal lobe, Oculomotor testing, Neuropsychological scores, Motor disability (UPDRS), Distractibility

Brief summary

The syndrome of distractibility is a behavioral disorder induced by a lesion or a dysfunction of the frontal lobe. This sign is frequent in patients with progressive supranuclear palsy (PSP), a neurodegenerative disorder with severe neuronal loss in the prefrontal cortex and cholinergic systems, in particular in the Meynert basalis nucleus. This could participate in the occurrence of the distractibility in these patients. The aim of this study is to evaluate the effect of the donepezil, an anticholinesterase, on the distractibility in PSP patients, by using oculomotor and neuropsychological assessments.

Interventions

DRUGdonepezil

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with PSP * Age \> 30 years old * Disease duration \< 5 years * Mini mental state (MMS) \> 24 * Antisaccades %: 40-80%

Exclusion criteria

* Other parkinsonian syndromes * MMS \< 24

Countries

France

Contacts

Primary ContactBertrand Gaymard, MD, PhD

gaymard@ccr.jussieu.fr33-142162218

Backup ContactSophie Rivaud-Pechoux, PhD

rivaud@ccr.jussieu.fr33-142162218

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026